Generated: April 30, 2017
|Title:||Use of HDAC inhibitors for the treatment of myeloma|
|Abstract:||The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I) ##STR00001## wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular, multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising an HDAC inhibitor and a compound effecting apoptosis of myeloma cells, preferably bortezomib, for simultaneous, separate or sequential use; to methods of treating myeloma; and to a pharmaceutical composition comprising said combination.|
|Inventor(s):||Atadja; Peter W (Acton, MA)|
|Assignee:||Novartis AG (Basel, CH)|
1. A method of treating multiple myeloma in a human patient in need thereof comprising administering in an amount which is synergistically effective, a combination of
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol3-yl)-ethyl]-amino]methyl]phenyl]-2- E-2-propenamide having the formula (III) ##STR00013## or a pharmaceutically acceptable salt thereof and bortezomib or a pharmaceutically acceptable salt thereof, wherein the
multiple myeloma is resistant to conventional therapy.
2. The method of claim 1, wherein the multiple myeloma is resistant to bortezomib.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.